There is no indication that the Oxford-AstraZeneca COVID-19 vaccine is linked to an increased risk of blood clots, the EU's medicines regulator has said.

For our comprehensive coverage and latest updates on COVID-19 click here.

The EU's medicines regulator also said the number of cases in vaccinated people was no higher than in the general population. The statement came after a number of countries, including Denmark and Norway, suspended the use of the jab, the BBC reported on 11 March. The suspension followed reports that a small number of people had developed clots after receiving the vaccine. There were also reports that a 50-year-old man had died in Italy after developing deep vein thrombosis (DVT) following a dose of the jab. "There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine," the European Medicines Agency (EMA) said on 11 March. "The vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing," it added.

It said there had been 30 cases of "thromboembolic events" among the five million Europeans who have received the jab. AstraZeneca said the drug's safety had been studied extensively in clinical trials. "Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine," a spokesperson said. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) said there was no evidence the vaccine had caused problems, and people should still go and get vaccinated when asked to do so. "Blood clots can occur naturally and are not uncommon. More than 11 million doses of the COVID-19 AstraZeneca vaccine have now been administered across the UK," said Phil Bryan of the MHRA.

The decision to temporarily suspend the use of AstraZeneca's jab has come as a setback for a European vaccination campaign that has stuttered into life, partly due to delays in delivery of the drug. However, there was some good news on 11 March as the EMA approved the single-shot Johnson & Johnson (J&J) vaccine. "More safe and effective vaccines are coming to the market," the EU Commission President tweeted, although some reports suggest that J&J vaccine shipments may not arrive until April.

Denmark, Norway and Iceland have temporarily suspended the rollout of the AstraZeneca vaccine. Italy and Austria, meanwhile, have stopped using certain batches of the drug as a precautionary measure. The suspensions in Italy and Austria involve different batches of the vaccine. Estonia, Latvia, Lithuania and Luxembourg have also suspended the use of the same batch as Austria.

In an earlier statement, the EMA said Denmark's decision was a "precautionary measure (taken) while a full investigation is ongoing into reports of blood clots in people who received the vaccine, including one case in Denmark where a person died". Italy's medicines body said its decision was "precautionary", adding that no link had been established between the vaccine and subsequent "serious adverse events". Two Italians are reported to have died after receiving the vaccine, and an unnamed source was quoted by a media outlet saying that their deaths are what prompted the temporary suspension.